Investors
corporate profile
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).
stock
snapshot
Additional stock info »
snapshot
02.22.2020 | 1:37 PM EST
Copyright West LLC. Minimum 15 minutes delayed.
Copyright West LLC. Minimum 15 minutes delayed.
Latest Corporate Presentation Get the Ovid primer— download our latest corporate presentation for investors. Download »
Explore the Ovid Pipeline The Ovid pipeline includes several candidates that would potentially be the first to make a meaningful impact in the lives of individuals with rare neurological conditions. View our pipeline »
Get Investor Updates Have the latest on the BOLD happenings at Ovid, from clinical trial endpoint and data announcements to corporate news, sent right to your inbox. Sign up now »
